RT Journal
A1 Kuehn BM
T1 INjections may take the bite out of malaria studies
JF JAMA
JO JAMA
YR 2012
FD December 12
VO 308
IS 22
SP 2325
OP 2325
DO 10.1001/jama.2012.105690
UL http://dx.doi.org/10.1001/jama.2012.105690
AB 
The phase I study, simultaneously published in the American Journal of Tropical Medicine and Hygiene (Roestenberg M et al. Am J Trop Med Hy. doi: 10.4269/ajtmh.2012.12-0613 [published online November 13, 2012]), involved 18 Dutch volunteers divided in 3 groups that received intradermal injections of 2500, 10 000, or 25 000 sporozoites. The sporozoites were produced by Sanaria, a biotechnology company, which raised infected mosquitos under aseptic conditions, purified the sporozoites from mosquito tissues, and preserved them in vials for injection. A total of 15 of 18 volunteers became infected with malaria, 5 of 6 in each inoculum group, with no observed differences in measures of infection between groups. All infected individuals were treated and recovered. Several reported headaches, likely due to the malaria infection, and 1 individual reported chest pain after malaria treatment. The trial was stopped while the trial's safety monitoring committee assessed the chest pain event, which was determined not to be a serious cardiac event, and the trial was resumed 3 days later, the authors noted.